bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Rating of "Hold" from Brokerages
bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Rating of "Hold" from Brokerages
Shares of bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) have been assigned a consensus recommendation of "Hold" from the seventeen brokerages that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $12.00.
據Marketbeat.com報道,藍鳥生物股份有限公司(納斯達克代碼:Blue-Get Rating)的股票已被涵蓋該股票的17家券商一致建議持有。兩名投資分析師對該股的評級為賣出,12名分析師發佈了持有評級,兩名分析師給予了買入評級,一名分析師給予了該公司強烈的買入評級。過去一年對該股進行評級的分析師的12個月目標價平均為12.00美元。
A number of research analysts recently weighed in on the stock. Morgan Stanley dropped their price target on shares of bluebird bio to $3.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 17th. Raymond James raised shares of bluebird bio from a "market perform" rating to an "outperform" rating and set a $8.00 price target on the stock in a research report on Tuesday, August 2nd. Barclays raised shares of bluebird bio from an "underweight" rating to an "equal weight" rating and raised their price target for the company from $3.00 to $5.00 in a research report on Friday. Finally, Wedbush dropped their price target on shares of bluebird bio from $10.00 to $8.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 10th.
一些研究分析師最近對該股進行了加碼。5月17日,週二,摩根士丹利在一份研究報告中將藍鳥生物的目標股價下調至3.00美元,並將該股的評級定為“減持”。8月2日,雷蒙德·詹姆斯在一份研究報告中將藍鳥生物公司的股票評級從“市場表現”上調至“跑贏大盤”,併為其設定了8.00美元的目標股價。在上週五的一份研究報告中,巴克萊將藍鳥生物的股票評級從減持上調至同等權重,並將該公司的目標價從3.00美元上調至5.00美元。最後,韋德布什在5月10日星期二的一份研究報告中將藍鳥生物的目標價從10.00美元下調至8.00美元,並將該股的評級定為中性。
bluebird bio Trading Up 22.1 %
藍鳥生物交易上漲22.1%
bluebird bio stock opened at $5.59 on Friday. bluebird bio has a 1-year low of $2.87 and a 1-year high of $26.00. The firm has a market capitalization of $399.41 million, a price-to-earnings ratio of -0.67 and a beta of 1.29. The firm's fifty day moving average price is $4.22 and its two-hundred day moving average price is $4.77.
藍鳥生物股票上週五開盤報5.59美元。藍鳥生物的一年低點為2.87美元,一年高位為26.00美元。該公司市值為3.9941億美元,市盈率為-0.67倍,貝塔係數為1.29。該公司的50日移動均線價格為4.22美元,200日移動均線價格為4.77美元。
Hedge Funds Weigh In On bluebird bio
對衝基金對藍鳥生物的看法
Several large investors have recently modified their holdings of BLUE. Amalgamated Bank purchased a new position in shares of bluebird bio in the first quarter worth about $39,000. US Bancorp DE increased its stake in shares of bluebird bio by 82.9% in the first quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 3,847 shares in the last quarter. Raymond James & Associates purchased a new position in shares of bluebird bio in the first quarter worth about $50,000. Penserra Capital Management LLC purchased a new position in shares of bluebird bio in the first quarter worth about $53,000. Finally, Bank of Montreal Can purchased a new position in shares of bluebird bio in the first quarter worth about $58,000. Hedge funds and other institutional investors own 96.38% of the company's stock.
幾家大型投資者最近調整了對Blue的持股。合併銀行在第一季度購買了藍鳥生物的新頭寸,價值約3.9萬美元。US Bancorp DE在第一季度增持了藍鳥生物的股份82.9%。US Bancorp DE現在持有這家生物技術公司的8486股股票,價值4.1萬美元,此前在上個季度又購買了3847股。Raymond James&Associates在第一季度購買了藍鳥生物的新頭寸,價值約5萬美元。Penserra Capital Management LLC在第一季度購買了藍鳥生物的新頭寸,價值約53,000美元。最後,蒙特利爾銀行可以在第一季度購買藍鳥生物的新頭寸,價值約5.8萬美元。對衝基金和其他機構投資者持有該公司96.38%的股票。
bluebird bio Company Profile
藍鳥生物公司簡介
(Get Rating)
(獲取評級)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
藍鳥生物公司是一家生物技術公司,研究、開發和商業化針對嚴重遺傳病的變革性基因療法。其用於治療嚴重遺傳性疾病的候選產品包括用於治療輸血依賴型β-地中海貧血的貝替貝吉基因Autotemcel;用於治療鐮狀細胞病(SCD)的lovotieglogene autemcel;以及用於治療大腦腎上腺腦白質營養不良的伊利伐多烯Autotemcel。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免費獲取StockNews.com關於藍鳥生物的研究報告(藍色)
- MarketBeat:回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升,是時候收購了嗎?
- Beyond Meat不是沒有希望,而且它很便宜
- 蘋果為何可能在年底創下歷史新高
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
獲得藍鳥生物日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對藍鳥生物和相關公司的最新新聞和分析師評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。